

Figure 1




Figure 2

The Enterohepatic Circulation with Key Transporter Proteins Mediating

Bile Acid Circulation






Figure 3

Bile Acid Conjugates of HMG-CoA Reductase Inhibitor



HR 780






R = OH S 3554


R = NHCH₂CO₂H S 3898

R = NHCH₂CH₂SO₃H S 4193

Figure 5





Z = CO₂H, P(O)(OR¹⁹)(OH)



Z = SO₃H, P(O)(OR¹⁹)(OH),
OSO₃H, OP(O)(OR¹⁹)(OH)

- R1 = α-OH ; R2 = α-OH (Cholate)
- R1 = β-OH ; R2 = H (Ursodeoxycholate)
- R1 = α-OH ; R2 = H (Chenodeoxycholate)
- R1 = H ; R2 = α-OH (Deoxycholate)
- R1 = β-OH ; R2 = α-OH (Ursocholate)
- R1 = H ; R2 = H (Lithocholate)

Figure 6



- R1 = α -OH ; R2 = α -OH (Cholate)
- R1 = β -OH ; R2 = H (Ursodeoxycholate)
- R1 = α -OH ; R2 = H (Chenodeoxycholate)
- R1 = H ; R2 = α -OH (Deoxycholate)
- R1 = β -OH ; R2 = α -OH (Ursocholate)
- R1 = H ; R2 = H (Lithocholate)

Figure 7





Figure 8



$R_1 = \alpha\text{-OH}$; $R_2 = \alpha\text{-OH}$ (Cholate)
 $R_1 = \beta\text{-OH}$; $R_2 = \text{H}$ (Ursodeoxycholate)
 $R_1 = \alpha\text{-OH}$; $R_2 = \text{H}$ (Chenodeoxycholate)
 $R_1 = \text{H}$; $R_2 = \alpha\text{-OH}$ (Deoxycholate)
 $R_1 = \beta\text{-OH}$; $R_2 = \alpha\text{-OH}$ (Ursocholate)
 $R_1 = \text{H}$; $R_2 = \text{H}$ (Lithocholate)

$Y = \alpha\text{-O}$
 $Y = \beta\text{-O}$
 $Y = \alpha\text{-NH}$
 $Y = \beta\text{-NH}$

$Z = \text{OH}$
 $Z = \text{N} \begin{array}{c} \text{CO}_2\text{H} \\ \text{H} \end{array}$
 $Z = \text{N} \begin{array}{c} \text{SO}_3\text{H} \\ \text{H} \end{array}$

Figure 9: Uptake of (8) (XP10569) or Glycochocholate by IBAT-Transfected CHO Cells




Figure 10: Uptake of (8) (XP10569) or Glycocholate by
LBAT-Transfected CHO Cells




Figure 11




Figure 12




Figure 13




Figure 14




Figure 16




Figure 17




Figure 18





Figure 19






Figure 21





Figure 22



Compounds (92) - (103) prepared following methods described in co-pending application "Bile Acid-Derived Compounds for Enhancing Oral Absorption and Systemic Bioavailability of Drugs" assigned to XenoPort, Inc.

Figure 23




Figure 24




Figure 26




Figure 27





Figure 28



$\text{R}' = \text{Na, R} = \text{H, Y} = 3\alpha\text{-O (143)}$ $\text{R}' = \text{Na, R} = \text{Me, Y} = 3\alpha\text{-O (147)}$ $\text{R}' = \text{Me, R} = \text{H, Y} = 3\alpha\text{-O (151)}$ $\text{R}' = \text{Me, R} = \text{Me, Y} = 3\alpha\text{-O (155)}$
 $\text{R}' = \text{Na, R} = \text{H, Y} = 3\beta\text{-O (144)}$ $\text{R}' = \text{Na, R} = \text{Me, Y} = 3\beta\text{-O (148)}$ $\text{R}' = \text{Me, R} = \text{H, Y} = 3\beta\text{-O (152)}$ $\text{R}' = \text{Me, R} = \text{Me, Y} = 3\beta\text{-O (156)}$
 $\text{R}' = \text{Na, R} = \text{H, Y} = 3\alpha\text{-NH (145)}$ $\text{R}' = \text{Na, R} = \text{Me, Y} = 3\alpha\text{-NH (149)}$ $\text{R}' = \text{Me, R} = \text{H, Y} = 3\alpha\text{-NH (153)}$ $\text{R}' = \text{Me, R} = \text{Me, Y} = 3\alpha\text{-NH (157)}$
 $\text{R}' = \text{Na, R} = \text{H, Y} = 3\beta\text{-NH (146)}$ $\text{R}' = \text{Na, R} = \text{Me, Y} = 3\beta\text{-NH (150)}$ $\text{R}' = \text{Me, R} = \text{H, Y} = 3\beta\text{-NH (154)}$ $\text{R}' = \text{Me, R} = \text{Me, Y} = 3\beta\text{-NH (158)}$

Figure 29




Figure 30





Figure 31






Figure 33

